UV Protection (Internal Photoprotection)

UV Protection (Internal Photoprotection)

Internal photoprotection describes a narrow and frequently overstated idea: certain dietary compounds accumulate in skin tissue and raise the threshold at which ultraviolet light produces measurable damage. The endpoints used are specific, chiefly the minimal erythema dose, the extent of ultraviolet-induced DNA damage, and the induction of matrix metalloproteinases that degrade dermal collagen. Eight graded entries appear here across 51 studies and roughly 5,220 participants, though nicotinamide and niacinamide are two names for the same amide of vitamin B3, so seven distinct compounds are represented. None of them is a substitute for sunscreen, and the literature is consistent on that point.

Nicotinamide holds Grade A on 5 studies and 686 participants, a small trial count carrying a strong rating because the studies were well controlled and the mechanism is direct. Ultraviolet exposure depletes cellular ATP and stalls DNA repair; nicotinamide replenishes nicotinamide adenine dinucleotide and restores repair capacity, while also limiting ultraviolet-induced immunosuppression. That is a different kind of protection from absorbing photons, and it operates after exposure rather than during it.

Four ingredients sit at Grade B. Omega-3 fatty acids rest on 8 studies and 400 participants, green tea extract on 8 and 450, astaxanthin on 7 and 350, and Polypodium leucotomos on 5 and 250. Astaxanthin has the most specific supporting trial in the set, a randomized double-blind placebo-controlled study of ultraviolet-induced skin deterioration in healthy people ^[1]. A systematic review of oral supplements and photoprotection surveys this whole category and describes the effect sizes as modest and the study designs as heterogeneous ^[2].

Vitamin E at 8 studies and 600 participants and selenium at 5 studies and 1,800 participants complete the set at Grade C. Selenium carries the largest participant count on the page while holding the weakest rating of the graded entries, a mismatch worth noting: participant volume in that literature comes largely from trials designed around other endpoints, not around cutaneous photoprotection.

The magnitude question governs everything else. Reported increases in minimal erythema dose in this literature are typically fractional, equivalent to a sun protection factor in the low single digits at best, against topical products formulated to reach thirty or fifty. Compounds that act systemically also cover skin that sunscreen misses and are not removed by sweat or water, which is the actual argument for them, but that argument only holds as a supplement to topical protection rather than a replacement for it.

Fair skin, high ambient ultraviolet, outdoor occupation, tanning bed use and a history of sunburns all raise baseline risk far more than any of these compounds lower it. The outcomes that matter here, actinic keratoses and skin cancer, are assessed clinically, and any new, changing or non-healing skin lesion requires medical evaluation.